Maria Eleni Paroikaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Eleni Paroikaki has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Eleftherios Mylonakis
Department of Medicine, Houston Methodist Hospital, Houston, TX, USA
1 shared publication - George Kroumpouzos
Department of Dermatology, Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA; APDerm, South Weymouth, Massachusetts, USA
1 shared publication - Sara Yumeen
Department of Dermatology Yale School of Medicine New Haven CT USA
1 shared publication - Shashank Bhargava
Venereology and Leprosy, Ujjain, Madhya Pradesh, India
1 shared publication
Latest Publications
- Open Access
- 15 March 2022
- Published by MDPI AG in Microorganisms
- Vol. 10 (3) , 624
Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review
Because of the increasing emergence of cutaneous reactions from COVID-19 vaccines worldwide, we investigated the published reports of these complications. We searched the PubMed, Google Scholar, and Scopus databases and the preprint server bioRxiv for articles on cutaneous complications linked to mRNA-1273 (Moderna), BNT162b2 (Pfizer–BioNTech), and AZD1222 (AstraZeneca–Oxford University) vaccines published until 30 September 2021. Eighty studies describing a total of 1415 reactions were included. Cutaneous reactions were more prevalent in females (81.6%). Delayed large local reactions were the most common complication (40.4%), followed by local injection site reactions (16.5%), zoster (9.5%), and urticarial eruptions (9.0%). Injection site and delayed large local reactions were predominantly caused by the mRNA-1273 vaccine (79.5% and 72.0%, respectively). BNT162b2 vaccination was more closely linked to distant reactions (50.1%) than mRNA-1273 (30.0%). Zoster was the most common distant reaction. Of reactions with adequate information for both vaccine doses, 58.3% occurred after the first dose only, 26.9% after the second dose only, and 14.8% after both doses. Overall, a large spectrum of cutaneous reaction patterns occurred following the COVID-19 vaccination. Most were mild and without long-term health implications. Therefore, the occurrence of such dermatologic complications does not contraindicate subsequent vaccination.
- 15 March 2022
- Published by MDPI AG in Microorganisms
- Vol. 10 (3) , 624
Open AccessCutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review
Because of the increasing emergence of cutaneous reactions from COVID-19 vaccines worldwide, we investigated the published reports of these complications. We searched the PubMed, Google Scholar, and Scopus databases and the preprint server bioRxiv for articles on cutaneous complications linked to mRNA-1273 (Moderna), BNT162b2 (Pfizer–BioNTech), and AZD1222 (AstraZeneca–Oxford University) vaccines published until 30 September 2021. Eighty studies describing a total of 1415 reactions were included. Cutaneous reactions were more prevalent in females (81.6%). Delayed large local reactions were the most common complication (40.4%), followed by local injection site reactions (16.5%), zoster (9.5%), and urticarial eruptions (9.0%). Injection site and delayed large local reactions were predominantly caused by the mRNA-1273 vaccine (79.5% and 72.0%, respectively). BNT162b2 vaccination was more closely linked to distant reactions (50.1%) than mRNA-1273 (30.0%). Zoster was the most common distant reaction. Of reactions with adequate information for both vaccine doses, 58.3% occurred after the first dose only, 26.9% after the second dose only, and 14.8% after both doses. Overall, a large spectrum of cutaneous reaction patterns occurred following the COVID-19 vaccination. Most were mild and without long-term health implications. Therefore, the occurrence of such dermatologic complications does not contraindicate subsequent vaccination.